
About MAbTree
MAbTree is a Healthcare company based in Zwingen (Switzerland) founded in 2019. It develops innovative monoclonal antibody technologies for cancer treatment. It operates on a B2B model. Its focus areas include Biotechnology, Medical Research and Cancer Treatments. Its legal entity in India is Mabtree Biologics India Private Limited (U24239TG2019PTC132087).
Company details
MAbTree develops innovative monoclonal antibody technologies for cancer treatment through providing healthcare solutions, advancing biotech innovations, conducting medical research, and cancer treatments. Prioritizing client-centric approaches, it ensures high-quality outcomes, innovation, and sustainable practices in its field. It continues to evolve, meeting industry challenges with strategic approaches.
- Headquarters Zwingen, Switzerland
- SectorsHealthcare
- Website mabtree.com
- Legal Name Mabtree Biologics India Private Limited
- Date of Incorporation 16 Apr, 2019
- Jurisdiction Hyderabad, Telangana, India
- Indian entity revenue₹41,511
FY 2023 · -96% YoY
- Indian entity net loss-₹77,054
FY 2023 · -186% margin
- Indian entity EBITDA₹25,933
FY 2023 · 62% margin
Associated legal entities of MAbTree
MAbTree operates through Mabtree Biologics India Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2023) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Mabtree Biologics India Private Limited CIN U24239TG2019PTC132087 | Active | 16 Apr 2019 | Hyderabad, Telangana | ₹0.0 Cr | 2 | View details |
Board of directors of Mabtree Biologics India Private Limited (MAbTree)
Mabtree Biologics India Private Limited is the primary company behind MAbTree. The board of Mabtree Biologics India Private Limited currently have 2 directors; the longest-serving is Alexander Ratna Monica, appointed in 2019. 3 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Alexander Ratna Monica DIN 08546494 | Director | 30 Aug 2019 | 7 yrs 2 mo | Mabtree Biologics India Private Limited |
| Subramanian DIN 08723399 | Director | 18 Mar 2020 | 6 yrs 8 mo | Mabtree Biologics India Private Limited |
Financials of MAbTree
Figures of Mabtree Biologics India Private Limited, the primary company behind MAbTree, for FY 2023. Revenue was ₹41,511 (-96% year on year). Net loss was -₹77,054 (-186% margin). EBITDA was ₹25,933 (62% margin). Revenue has grown at a compounded annual rate of -75% over three years.
- ₹41,511Revenue · FY 2023 · -96% YoY
- -₹77,054Net loss · -186% margin
- ₹25,933EBITDA · 62% margin
- ₹1 LakhPaid-up capital
- -75%Revenue CAGR, 3 years
Balance sheet, profit and loss, cash flow and ratios of Mabtree Biologics India Private Limited are on its company page.
Detailed financial statements for MAbTree
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about MAbTree
MAbTree was founded in 2019.
MAbTree is headquartered in Zwingen, Switzerland. It is registered at Zwingen, Basel-landschaft, Switzerland.
The primary company behind MAbTree, Mabtree Biologics India Private Limited, reported revenue of βΉ41,511 for FY 2023, down 96% year on year.
MAbTree develops innovative monoclonal antibody technologies for cancer treatment through providing healthcare solutions, advancing biotech innovations, conducting medical research, and cancer treatments. Prioritizing client-centric approaches, it ensures high-quality outcomes, innovation, and sustainable practices in its field. It continues to evolve, meeting industry challenges with strategic approaches.
MAbTree operates through Mabtree Biologics India Private Limited.
The legal entities of MAbTree currently have 2 directors, including Alexander Ratna Monica, Subramanian.